MedTrace Logo

Zelquistinel in the Treatment of Adults With Major Depressive Disorder

NCT03726658 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2026-04-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder

Conditions

Interventions

DRUG

AGN-241751

AGN-241751 is supplied in tablet form

DRUG

Placebo

Placebo is supplied in tablet form

Sponsors & Collaborators

  • Syndeio Biosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Ronald M Burch, MD PhD · Syndeio Biosciences, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-08
Primary Completion
2019-10-23
Completion
2019-10-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03726658 on ClinicalTrials.gov